Status: One Wales interim decision | |
Using the agreed starting and stopping criteria, vedolizumab (Entyvio®) can be made available within NHS Wales for the treatment of immune checkpoint inhibitor induced grade 3-4 enterocolitis, where symptoms have not responded to first line immunosuppression with corticosteroids and infliximab, or when infliximab is unsuitable. The risks and benefits of the off-label use of vedolizumab (Entyvio®) for this indication should be clearly stated and discussed with the patient to allow informed consent. Providers should consult the relevant guidelines on prescribing unlicensed medicines before any off-label medicines are prescribed. This advice will be reviewed after 12 months or earlier if new evidence becomes available. |
|
Medicine details |
|
Medicine name | vedolizumab (Entyvio®) |
Formulation | powder for solution for infusion |
Reference number | OW22 |
Indication | Treatment of immune checkpoint inhibitor induced grade 3-4 enterocolitis, where symptoms have not responded to first line immunosuppression with corticosteroids and/or other immunosuppressant drugs like infliximab, or when infliximab is unsuitable |
Company | Takeda UK Ltd |
BNF chapter | Gastro-intestinal system |
Submission type | One Wales |
Status | One Wales interim decision |
Advice number | OW22 |
Date of issue | 02/02/2023 |